SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 (GLOBE...
Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo...
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0762 | -38.8379204893 | 0.1962 | 0.2098 | 0.1146 | 5779240 | 0.1835058 | CS |
4 | 0.0494 | 69.9716713881 | 0.0706 | 0.4477 | 0.0652 | 190605873 | 0.24070053 | CS |
12 | 0.0347 | 40.6799531067 | 0.0853 | 0.4477 | 0.0636 | 69826169 | 0.2240067 | CS |
26 | -0.87 | -87.8787878788 | 0.99 | 1.02 | 0.0636 | 35129005 | 0.22415974 | CS |
52 | -5.13 | -97.7142857143 | 5.25 | 12.38 | 0.0636 | 22209540 | 0.26732521 | CS |
156 | -5.13 | -97.7142857143 | 5.25 | 12.38 | 0.0636 | 22209540 | 0.26732521 | CS |
260 | -5.13 | -97.7142857143 | 5.25 | 12.38 | 0.0636 | 22209540 | 0.26732521 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約